Rasburicase versus intravenous allopurinol for non-malignancy-associated acute hyperuricemia in paediatric cardiology patients.
Jeffrey D MossMay WuDavid M AxelrodDavid M KwiatkowskiPublished in: Cardiology in the young (2020)
In a limited paediatric cardiac cohort, the use of rasburicase was associated with a greater reduction in uric acid levels and associated with a lower cost compared to IV allopurinol.
Keyphrases
- uric acid
- metabolic syndrome
- intensive care unit
- end stage renal disease
- emergency department
- ejection fraction
- prognostic factors
- peritoneal dialysis
- respiratory failure
- high dose
- patient reported outcomes
- cardiac surgery
- drug induced
- low dose
- hepatitis b virus
- acute kidney injury
- atrial fibrillation
- extracorporeal membrane oxygenation